Search

Your search keyword '"Richard Schlenk"' showing total 8 results
Start Over Author "Richard Schlenk" Topic diseases of the blood and blood-forming organs
8 results on '"Richard Schlenk"'

1. S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST

Author

Richard Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, and Harry P. Erba

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA

Author

Sabine Kayser, Chiara Sartor, Fabio Giglio, Alessandro Bruno, Jonathan Webster, Patrizia Chiusolo, Francesco Saraceni, Selene Guerzoni, Lara Pochintesta, Erika Borlenghi, Giovanni Marconi, Irene Zacheo, Marco Cerrano, Prassede Salutari, Francesco Restuccia, Mariachiara Abbenante, Mark J Levis, Richard Schlenk, and Cristina Papayannidis

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. P538: FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Author

Maximilian Roehnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Roellig, Johannes Schetelig, Friedrich Stoelzel, Richard Schlenk, Martin Bornhaueser, Malte von Bonin, and Uta Oelschlaegel

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS

Author

Sabine Kayser, Khaled Sanber, Giovanni Marconi, Agnese Mattei, Marlise Luskin, Amar Kelkar, Marco Cerrano, Chiara Sartor, Fabio Giglio, Marta Riva, Lorenzo Rizzo, Francesco Saraceni, Selene Guerzoni, Federica Lessi, Erika Borlenghi, Alexander Perl, Mark J Levis, Cristina Papayannidis, Tania Jain, and Richard Schlenk

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

Author

Claire Harrison, John Mascarenhas, Daniela Cilloni, Richard Schlenk, Brian Jacoby, Robert J Slack, Vassilios Aslanis, Bhupinder Singh, Bertil Lindmark, Srdan Verstovsek, and Raajit K Rampal

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

6. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial

Author

Leo Ruhnke, Christoph Röllig, Sylvia Herold, Tim Sauer, Christian H. Brandts, Björn Steffen, Kerstin Schäfer-Eckart, Stefan W. Krause, Mathias Hänel, Albrecht Reichle, Sebastian Scholl, Andreas Neubauer, Jan-Henrik Mikesch, Johannes Schetelig, Friedrich Stölzel, Michael Kramer, Annett Haake, Julia Frimmel, Alwin Krämer, Richard Schlenk, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow, Daniela Aust, Martin Bornhäuser, Gerhard Ehninger, and Christian Thiede

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

7. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia

Author

Felicitas Thol, Michaela Scherr, Aylin Kirchner, Rabia Shahswar, Karin Battmer, Sofia Kade, Anuhar Chaturvedi, Christian Koenecke, Michael Stadler, Uwe Platzbecker, Christian Thiede, Thomas Schroeder, Guido Kobbe, Gesine Bug, Oliver Ottmann, Wolf-Karsten Hofmann, Nicolaus Kröger, Walter Fiedler, Richard Schlenk, Konstanze Döhner, Hartmut Döhner, Jürgen Krauter, Matthias Eder, Arnold Ganser, and Michael Heuser

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2015
Full Text
View/download PDF

8. Therapy-related myeloid neoplasms following treatment with radioiodine

Author

Thomas Schroeder, Andrea Kuendgen, Sabine Kayser, Nicolaus Kröger, Friederike Braulke, Uwe Platzbecker, Viola Klärner, Fabian Zohren, Detlef Haase, Michael Stadler, Richard Schlenk, Akos G. Czibere, Ingmar Bruns, Roland Fenk, Norbert Gattermann, Rainer Haas, Guido Kobbe, and Ulrich Germing

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Background Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment.Design and Methods We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine treatment, whose data were reported to the Duesseldorf Myelodysplastic Syndromes Register (8 of 3814 patients) and five other German Myelodysplastic Syndromes centers (n=31) between 1982 and 2011. These data were compared with those from 165 patients from our Myelodysplastic Syndromes Register with therapy-related myeloid neoplasms following chemotherapy (n=90), radiation (n=30), or radiochemotherapy (n=45).Results With a median latency of 79 months, 18 patients developed therapy-related acute myeloid leukemia and 21 presented with therapy-related myelodysplastic syndromes (8 refractory anemia with excess blasts I/II, 6 refractory anemia with multilineage dysplasia, 3 myelodysplastic syndromes with del(5q), 1 refractory anemia, 1 refractory anemia with ring sideroblasts, 1 chronic myelomonocytic leukemia II, 1 myelodysplastic/myeloproliferative neoplasm unclassifiable). Risk assessment according to the International Prognostic Scoring System was low-risk in 23%, intermediate-1 in 29%, intermediate-2 in 35%, and high-risk in 13%. Karyotype was abnormal in 68%, with chromosomes 7 (30%), 5 (26%), 8 (26%) and 3 (17%) being most frequently affected. No differences in the distribution of gender, World Health Organization subtype, acute myeloid leukemia progression, International Prognostic Scoring System score, and cytogenetic risk were observed between patients with therapy-related myeloid neoplasms following radioiodine or other treatment modalities. Of 17 patients who received induction chemotherapy, 71% were refractory to this treatment or died from treatment-related toxicity. The median overall survival in the entire group was 21.7 months (95%-CI 10.5–33 months) and did not differ significantly in comparison to the survival of patients with therapy-related myeloid neoplasms following other cytotoxic treatments. Patients with therapy-related acute myeloid leukemia had significantly inferior overall survival (12.4 versus 28.7 months, P=0.002).Conclusions Patients developing a therapy-related myeloid neoplasm after radioiodine treatment usually present with biological characteristics similar to those seen in patients with therapy-related myeloid neoplasms following other cytotoxic treatment modalities, associated with a low response rate to induction chemotherapy and poor prognosis.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results